Sugi Predict

Sugi Predict / Compounds / SCHEMBL4593501

SCHEMBL4593501

SCHEMBL4593501

Fc1ccc(-n2nc(-c3ccccc3)c(Br)c2-c2ccncc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRAF P15056 7/20 0.55
▸ KDR P35968 7/20 0.55
▸ SRC P12931 6/20 0.55
▸ MAPK14 Q16539 8/20 0.47
▸ MAPK10 P53779 1/20 0.47
▸ PTGER1 P34995 1/20 0.45
▸ CA1 P00915 2/20 0.45
▸ CA2 P00918 2/20 0.45
▸ CDK1 P06493 1/20 0.44
▸ CDK4 P11802 1/20 0.44
▸ CCNB1 P14635 1/20 0.44
▸ CCNA2 P20248 1/20 0.44
▸ CCND1 P24385 1/20 0.44
▸ CDK2 P24941 1/20 0.44
▸ CDK7 P50613 1/20 0.44
▸ CCNH P51946 1/20 0.44
▸ EGFR P00533 1/20 0.44
▸ RAF1 P04049 1/20 0.44
▸ ADORA3 P0DMS8 1/20 0.44
▸ ADORA2A P29274 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20678524 0.82 CA1 (0.56) SRCPTGER1CA1CA2CCNA2
SCHEMBL6525798 0.81 MAPK13 (0.48) BRAFKDRSRCMAPK14GSK3B
SCHEMBL6515238 0.81 CA1 (0.63) PTGER1CA1CA2CCNA2CDK2
SCHEMBL15823981 0.76 MAPK14 (0.58) MAPK14MAPK10MAPK13MAPK12MAPK11
SCHEMBL5214655 0.74 SRC (0.50) BRAFKDRSRCPTGER1CDK1
SCHEMBL27736602 0.74 CA1 (0.43) KDRMAPK10PTGER1CA1CA2
SCHEMBL6623278 0.72 SRC (0.58) BRAFKDRSRCMAPK14MAPK10
SCHEMBL6176869 0.71 BRAF (1.00) BRAFKDRSRCMAPK14MAPK10
SCHEMBL14833476 0.71 BRAF (1.00) BRAFKDRSRCMAPK14MAPK10
SCHEMBL6772362 0.70 MAPK14 (0.49) BRAFKDRSRCMAPK14MAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030153569-A1 Novel pyrazole and pyrazoline substituted compounds SMITHKLINE BEECHAM CORPORATION 2003-08-14 — — US claimed
US-20020156104-A1 CSBP/p38/RK kinase inhibitors SMITHKLINE BEECHAM CORPORATION 2002-10-24 — — US claimed
EP-1539121-A4 METHODS OF PROMOTING OSTEOGENESIS SCIOS INC (US) 2008-08-13 — — EP disclosed
US-20080108658-A1 METHODS OF PROMOTING OSTEOGENESIS PROTTER ANDREW A 2008-05-08 — — US disclosed
EP-1583535-A4 METHODS FOR TREATING DIABETES SCIOS INC (US) 2008-03-19 — — EP disclosed
US-20080039461-A1 Treatment of pain by inhibition of p38 map kinase PROTTER ANDREW A 2008-02-14 — — US disclosed
US-7268139-B2 Methods of promoting osteogenesis SCIOS, INC. (US) 2007-09-11 — — US disclosed
US-7244441-B2 Stents and intra-luminal prostheses containing map kinase inhibitors SCIOS, INC. (US) 2007-07-17 — — US disclosed
EP-1676574-A2 Methods for promoting survival of transplanted tissues and cells Johnson & Johnson Vision Care, Inc. (US) 2006-07-05 — — EP disclosed
US-20060019971-A1 Treatment of cardiovascular disease with inhibitors of p38 kinase SCIOS INC. 2006-01-26 — — US disclosed
EP-1583535-A2 METHODS FOR TREATING DIABETES SCIOS INC. (US) 2005-10-12 — — EP disclosed
EP-1539121-A2 METHODS OF PROMOTING OSTEOGENESIS SCIOS INC. (US) 2005-06-15 — — EP disclosed
US-20040171659-A1 Methods for treating diabetes SCIOS, INC. 2004-09-02 — — US disclosed
US-20040162289-A1 Methods of promoting osteogenesis UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY 2004-08-19 — — US disclosed
US-6774127-B2 TREATING CYTOKINE MEDIATED DISEASES SMITHKLINE BEECHAM CORPORATION 2004-08-10 — — US disclosed
WO-2004019873-A9 METHODS OF PROMOTING OSTEOGENESIS SCIOS INC (US) 2004-06-24 — — WO disclosed
US-20040122008-A1 Treatment of pain by inhibition of p38 MAP kinase SCIOS, INC. 2004-06-24 — — US disclosed
WO-2004053107-A2 METHODS FOR TREATING DIABETES SCIOS INC. (US) 2004-06-24 — — WO disclosed
WO-2004019873-A2 METHODS OF PROMOTING OSTEOGENESIS SCIOS INC. (US) 2004-03-11 — — WO disclosed
US-20020156104-A1 CSBP/p38/RK kinase inhibitors SMITHKLINE BEECHAM CORPORATION 2002-10-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060019971-A1 Treatment of cardiovascular disease with inhibitors of p38 kinase MAPKAPK5, MAPK1, MAPKAPK2 BRAF 1225/4885KDR 1333/4885SRC 770/4885
US-20080108658-A1 METHODS OF PROMOTING OSTEOGENESIS MAPK1, BMP2, MAPK3 BRAF 2710/4885KDR 4399/4885SRC 334/4885
US-20040162289-A1 Methods of promoting osteogenesis MAPK1, BMP2, MAPK3 BRAF 2710/4885KDR 4399/4885SRC 334/4885
US-20030153569-A1 Novel pyrazole and pyrazoline substituted compounds PDXK, COQ8A, PDK3 BRAF 144/4885KDR 2247/4885SRC 2290/4885
US-20040122008-A1 Treatment of pain by inhibition of p38 MAP kinase OPRK1, OPRL1, MAPK3 BRAF 706/4885KDR 4446/4885SRC 802/4885
US-20080039461-A1 Treatment of pain by inhibition of p38 map kinase OPRK1, OPRL1, MAPK3 BRAF 706/4885KDR 4446/4885SRC 802/4885
US-20040171659-A1 Methods for treating diabetes SLC5A2, MAPK4, MAPK3 BRAF 239/4885KDR 3787/4885SRC 723/4885
US-20020156104-A1 CSBP/p38/RK kinase inhibitors MAPKAPK2, MAPKAPK3, MAPKAPK5 BRAF 119/4885KDR 2269/4885SRC 604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.